$300M tax on air fares for HIV/AIDS drugs

24 September 2006

Five countries have agreed to implement a French government plan to tax airfares in order to raise funds for HIV/AIDS drugs, as well as treatment for tuberculosis and malaria, in the developing world.

The proposal, the brainchild of France's President Jacques Chirac, is also supported by Brazil, Chile, Norway and the UK. Funds will be channelled via Unitaid, a new Geneva, Switzerland-based organization. The target is to provide treatment for 100,000 AIDS sufferers, 100,000 with antiretroviral drug-resistant AIDS, 150,000 infected with TB and 28 million malaria victims, all of them children. Unitaid intends to use its purchasing power to negotiate favorable prices for the appropriate drugs.

Of the Unitaid budget of $300.0 million for the coming year, France is providing $250.0 million and the UK a further $25.0 million. A tax of 4 euros ($5.07) per international economy passenger and 40 euros per first class passenger are being levied already in France.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight